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ALOPECIA AREATA: AN OVERVIEW
Chaya Gestetner
Abstract
This review seeks to find the most efficient treatment for alopecia areata. Alopecia is not very well
understood as demonstrated by the unsatisfactory treatment options. The author reviewed many studies
with different treatment options and concluded that treatment with Diphenylcyclopropenone (DPCP), a
topical sensitizer, has the best results and that extensive research into the pathogenesis of alopecia areata
is still necessary and may result in better treatment options for those afflicted with the disease.
Alopecia Areata: an Overview
Hair is an important part of the human presence; it is the crowning glory that sits upon one’s
temples. Therefore, hair loss of any sort is extremely painful and embarrassing. Most people
automatically correlate hair loss with cancer treatments or old age. However, there is another less known
mechanism of hair loss; alopecia areata, an autoimmune disease, causes partial or complete hair loss to
occur. Alopecia areata affects approximately four and a half million people in the United States (Etzioni
et.al. 2012). The prevalence of this disease raises many questions, namely: Why does this spontaneous
hair loss occur? Does alopecia areata occur in response to stress, or is it due to genetic factors? How can
it be treated?
The Hair Cycle
In order to understand the nuances of the pathogenesis of alopecia areata, it is necessary to be
familiar with the normal hair cycle. Normal hair follicles go through several stages; the anagen or
growth phase, the catagen or regression phase, and the telogen or rest phase. Then the follicle goes
through a fourth, shedding phase, called the exogen phase.
The dermal papilla of the hair follicle consists of an oval cluster of mesenchymal cells. A
substance that is full of acid mucopolysaccharides surrounds the mesenchymal cells. The whole
structure is at the very bottom of the follicle, and is surrounded by the matrix cells. The dermal papilla is
responsible for initiating and directing hair growth (Alaiti, 2011). Figure 1 depicts the location of the
dermal papilla on a healthy hair follicle.

Figure 1- structure of hair follicle (Promocell).
Chaya Gestetner graduated in June of 2013 with a B.S. in Biology. She will be attending LIU college of
Pharmacy.
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During the anagen phase, the dermal papilla grows (Botchkarev, Cotsarelis 2012). The hair
matrix, of the follicle, consists of many epidermal cells that then proliferate rapidly into six different
types of cells. These daughter cells move upward and become part of the Inner Root Sheath (IRS) and
the Hair Shaft (HS). The HS cells shed their organelles and become stratified with bundles of
cysteine-rich hair keratin filaments. The IRS also keratinizes by forming trichohyalin granules. Soon
the matrix cells cannot proliferate any further, and the follicle enters the catagen stage (Alonso, Fuchs
2006).
In Catagen, the epithelial cells in the outermost epithelial layer undergo apoptosis (Botchkarev
et.al. 1997). The Hair bulb becomes keratinized forming a club hair. This cuts the follicle off from its
blood supply. The club hair then travels upwards, pushed forward by a column of epithelial cells. At first
the column of cells is thick but soon begins to shrink upward becoming secondary follicular germ cells
(Alonso, Fuchs 2006) (Alaiti, Samer 2011).
After the club hair is formed, the telogen phase begins. The follicle prepares to shed the hair
from the scalp (Botchkarev, Cotsarelis 2012). The dermal papilla and secondary germ cells form the
telogen germinal unit.
Exogen is the shedding phase. In this phase, the old hair is shed after the new anagen phase
begins.
Figure 2 illustrates the four stages of the normal hair cycle.

Figure 2 - The Stages of the Normal Hair Cycle (Australian Skin Clinics).
In alopecia areata, the general hair cycle is disrupted and disfigured. The follicles show signs
of dystrophy in the anagen phase. This is caused by an inflammatory infiltrate that surrounds the hair
bulb, the base of the hair follicle. The infiltrate is mainly composed of T-cells, but it also includes
eosinophils, mast cells, plasma cells and Langerhans cells. There is also some penetration of
lymphocytes to intrafollicular areas (McElwee, Wang 2011). Most cells enter and attack the dermal
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papilla and hair matrix, causing apoptosis and necrosis of the follicle’s epithelium. The inflammation
cripples the hair shaft, eventually forming the exclamation-point hairs that are associated with alopecia
areata (Dy, Whiting 2011).
Although old hair is only shed after the new growth begins in healthy hair follicles, in follicles
with alopecia areata, exogen commonly occurs before anagen begins. This results in a state where no
visible hair fiber is left in the follicle. This state is called kenogen (McElwee, Wang 2011).
In the most severe form of alopecia areata, all body hair is lost. This condition is referred to as
alopecia universalis. This condition is rare.
Diagnosis Of Alopecia Areata
The first step in treating any disease is to diagnose it. Alopecia areata is identified through a
physical examination. In its general form, alopecia areata is recognized by its typical hair loss patterncausing round or oval, smooth patches of hair loss that are most noticeable on the scalp and eyebrows
(Etzioni et.al. 2012). Figures 3a and 3b depict the pattern of hair loss triggered by alopecia areata.
	
  

a	
  

b	
  

Figure 3a- alopecia areata symptoms http://www.curespotbaldness.com
Figure 3b- alopecia areata symptoms http://www.curespotbaldness.com
First, the dermatologist will perform the “hair pull” test. The doctor will use his/her thumb and
index fingers to gently tug at hairs in various areas of the scalp. On a healthy scalp, between 2 and 6
hairs will detach. If more hairs fall out, that indicates excessive shedding. The dermatologist will then
proceed to study the hairs underneath a microscope. This is done to determine the growth phase of the
hair. Normally, the hairs that fall out easily are in the telogen phase. Anagen roots are stronger, younger
and still growing. If the pulled roots are in the anagen phase, this is indicative that there is a serious
health problem (Tosti, Gray 2007)
A newer diagnostic tool is known as videodermoscopy; it involves a high-definition video
camera allowing for a direct, magnified examination of the scalp (Ross et.al. 2006). Videodermoscopy is
a helpful diagnostic tool when trying to differentiate between similar diseases. In the case of alopecia,
videodermoscopy can be used to differentiate alopecia areata from other causes of patchy alopecia. Use
of the technology shows that in cases of alopecia areata, numerous yellow dots, known as degenerate
follicular keratinocytes, are found on the scalp surface (Tosti, Gray 2007). Figure 4 shows the
exclamation mark hairs and yellow dots found on patients with alopecia areata.
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Figure 4- Alopecia areata- standard exclamation mark hairs (Tosti, Gray .2007)
The dermatologist will also examine the patient’s nails, as alopecia areata is thought to be
associated with nail dystrophy (Bergfeld, 2009). At times, nail distortion is one of the first signs of
alopecia areata. Symptoms include; tiny dents on nails, white spots, lines, roughness, loss of natural
shine, and splitting.
Causes
The etiology of alopecia areata is complex: determinants of the disease include genetic factors,
psychological factors, autoimmune processes, and infectious factors. Despite active research on alopecia
areata, investigators still have a limited understanding of its pathogenesis and etiology.
Genetics
A genetic basis for alopecia areata was indicated by statistical studies which showed that
relatives of a patient diagnosed were more likely to have the condition themselves. For example, in one
study of 206 patients with alopecia areata, 5.5% of their immediate family members (parents, siblings,
children) were also stricken with alopecia. Of the 206 patients, forty-five had at least one immediate
family member with the disease (Blaumeiser et.al. 2006).
After early statistical studies of alopecia areata showed high family-linked prevalence for the
disease, researchers began searching for genes linked to its outbreak. In 2011, researchers performed
the first genome-wide association study of alopecia areata. This identified 139 significant single
nucleotide polymorphisms (SNPs) in eight sections throughout the genome, which implicated genes of
the immune system and the hair follicle. For example, one important find was the involvement of
chromosome 2q33.2 (CTLA4). CTLA4 becomes displayed following T cell activation (Petukhova et.al
2011). It is assumed that CTLA4 plays a critical role in the onset and maintenance of alopecia areata.
CTLA4 binds CD80 and CD86 on antigen-presenting cells. One study injected monoclonal antibodies
(mAb’s) against antigen presenting cell (APC) surface markers CD80 and CD86 as well as a
monoclonal anti-CTLA4 antibody into mice that were predisposed to develop alopecia areata in an
attempt to interfere with the interactions between T cells and antigen presenting cells that involve
CTLA4. The treatment prevented the onset of the disease, proving that CTLA4 plays a big role in the
pathogenesis of the disease (Sundberg et al. 2011).
Psychological Factors
In a group of 45 patients with alopecia areata, 31 identified stressful events, including death of a
parent, family disputes, and exams. Most events occurred less than three months before the onset of the
disease (Manolache, Benea 2007). Another study investigated the effects of a heat treatment, a stressful
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event, on mice that were predisposed to develop alopecia areata. Petroleum jelly was applied to the
mural skin to improve conductance. Then, heat was applied with a copper cylinder connected to a
precision water bath (119.3°F) for twenty minutes daily for 12 consecutive days. Researchers then used
an icepack to cool the area (Wikramanayake et.al. 2012). While the mice generally begin to show signs
of alopecia at 18 months, mice that underwent the treatment developed signs of the disease at least ten
months earlier than normal. This study suggests that stress does not cause alopecia areata to occur, but it
may help promote onset of the disease (Wikramanayake et.al. 2010).
One question arises from this study: Perhaps the heat itself destroys the hair follicle, and that’s
what caused the hair loss. The study used a control; forty mice were treated with room temperature
water. Of these mice, only 7% developed the disease. Was the higher hair loss rate in heat-treated mice
due to the stress or to the heat itself? While it is possible that some of the hair loss was due to the heat
itself, the presence of alopecia areata was confirmed when histological studies showed that there were
leukocyte infiltrates in anagen hair follicles (Wikramanayake et.al. 2010).
Autoimmunity
Research results overwhelmingly point to the conclusion that alopecia areata is an autoimmune
disease. There are many indications supporting this belief:
Firstly, as mentioned previously, a thick cluster of lymphocytic cells surrounds alopecia areataaffected hair follicles. These include antigen presenting cells (APCs) such as macrophages and
Langerhans cells, which are sometimes even found within the hair follicle.
Another reason is that alopecia areata is associated with other autoimmune diseases such as
thyroid disorders and vitiligo (Thomas et.al. 2008). Alopecia areata also responds to immunomodulatory
treatments such as corticosteroids, light phototherapy, and non-specific irritants such as anthralin and
inducers of contact dermatitis (Lu et.al. 2006).
One proposed hypothesis is that the follicles’ immune-privileged state is compromised in
alopecia areata. Thus, normally innocuous hair-follicle-specific proteins are exposed to activated
antigen-presenting cells. The antigen-presenting cells capture and process these proteins, which are then
expressed on major histocompatibility complexes class II and I as antigens (Lu et.al. 2006). These
antigens originate in the body and are known as autoantigens (Hordinsky, Ericson 2004). The exposed
antigens activate T cells; they proliferate and travel to the skin forming the infiltrate around
anagen-stage hair follicles, disrupting hair growth and the hair follicle dystrophy. As a result, the anagen
phase is cut short and the follicles enter an early telogen phase. This cycle continues and hair loss occurs
(Lu et.al. 2006).
A few questions arise from the previous paragraph. The first question is: what stimulates the
breakdown of immune privilege in the hair follicle? The second question is: What causes the
dysfunction of immunoregulation that is supposed to delete autoreactive T cells? A third question is:
which proteins function as the autoantigens in alopecia areata?
These questions are important because their answers can give insight on how to treat the disease.
For example, if the disease initiation were caused by loss of immune privilege in the follicle, a possible
therapeutic mechanism would be to replace or reinforce immune privilege. This can be done through
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promoting immune-protective cytokines and cell ligands, which reduce the exposure of follicular
antigens (Lu et.al. 2006).
The first two questions can be explained by genetic studies, as discussed previously. The third
question is the subject of a lot of current research on alopecia areata. If the autoantigens involved in
alopecia areata were identified, new treatment strategies can be developed. It could be possible to
modify or inhibit autoantigen presentation. Another method mentioned by Lu and his co-authors would
be to expose the immune system to such large amounts of antigen polypeptides that would then overload
the receptors of pathogenic, autoreactive lymphocytes and could theoretically cause anergy or death of
these cells (Lu et.al. 2006).
However, Hordinsky and Ericson (2004), mention that an autoantibody has yet to be implicated
in alopecia areata. Gilhar and Kalish (2006), came to the logical conclusion that the autoantigen
involved should be melanocyte derived. This is because generally alopecia areata affects only pigmented
hair.
In a separate experiment, researchers used immunoperoxidase stains to test scalp samples for
melanocyte density. They found that scalp samples from alopecia areata patients had a decreased
number of follicular melanocytes. The researchers did not know if the decrease in melanocyte density is
caused by the immune attack or by the rapid hair cycles that characterize the disease (Trautman et.al.
2009). Although these results are not conclusive, they do back the theory that autoantigens in alopecia
areata may be derived from melanocytes.
Another recent study isolated a structural protein, trichohyalin, as a potential autoantigen
involved in alopecia areata, as well as Keratin 16. Researchers used mass spectrometry on ten samples;
these showed strong reactivity to the protein trichohyalin in all alopecia areata sera (Leung et.al. 2010).
Trichohyalin is a 200-kDa protein of the IRS. It is a doublet in some animals but is a single polypeptide
in humans (O’Keefe et.al. 1993). Moreover, immunofluorescense studies with alopecia areata sera and a
monoclonal antibody to trichohyalin supported the theory as the immunoreactivity in the alopecia areata
sera was in the same location as the trichohyalin in the inner root sheath of the hair follicle (Leung et.al.
2010). IgG tightly binds the inner root sheath and reacts with a 200/220kDa doublet by immunoblotting
in all species studied, including canines affected by alopecia areata (Tobin et.al. 2003).
With further research, one of the above possibilities may be implicated as the definitive
autoantigen in alopecia areata. This would promote new treatments directed toward the autoantigen itself
or toward the lymphocytic cells that respond to it.
Hair-follicle-specific autoantibodies are found in the peripheral blood of individuals with the
disease. Although some are found in normal individuals, autoantibodies such as hair-follicle specific
IgGs are found in higher concentrations in alopecia areata patients than in non-affected individuals (Lu
et.al. 2006). These appear to be targeting intracellular antigens. Abnormal deposits of complement and
immunoglobulin IgG and IgM were also found in 92% of 12 patients with alopecia areata (Bystryn et.al.
1979). These findings indicate that autoimmune processes are responsible for the hair loss associated
with alopecia areata.
One study questions this theory. In this study forty nude mice were grafted with scalp skin
transplants from patients with alopecia areata. One group of mice was given intravenous injections of
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serum from patients, and the other group was given normal serum. Although deposition of
immunoreactants such as immunoglobulins and complement was noted in hair follicles of mice who
received patients’ serum, hair growth was observed in most cases. The researchers concluded that
immunoreactants do not inhibit hair growth in alopecia areata (Gilhar, Pillar 1992).
Although hair follicle-specific antibodies may not be responsible for the initiation of alopecia
areata, their production and presence in the hair follicle may stimulate extra damage or even maintain
the disease. Tobin and his colleagues performed a study to further understand the pathogenic potential
of these antibodies. They conducted the passive transfer of serum from horses affected by alopecia
areata into the anagen skin of C57BL/ 10 mice. Although normal hair regrowth was observed in mice
injected with the normal serum, hair did not regrow in the area around the injection site of the alopecia
areata serum even 13 weeks after the injection (Tobin et.al. 1998). The evidence shown here supports
the idea that anti-hair follicle autoantibodies promote the pathogenesis of alopecia areata.
Infectious Factors
The theory that alopecia areata was caused by an infectious disease was the leading theory until
recently. In 1899, sixty-three out of sixty-nine teenage girls in a homeless shelter found bald patches on
their heads (Bowen 1899). In 1971, there were reports of a widespread breakout of alopecia areata
(Messenger, McDonagh 1997). Scientists of the time believed that alopecia areata was a contagious
disease.
After one study where scientists tested ten scalp biopsies for the presence of cytomegalovirus
DNA, alopecia areata was thought to be associated with the viral infection. Out of ten samples, nine
tested positively- leading to the belief that CMV infection leads to alopecia areata. However, in 1996,
when the above study could not be replicated, it was determined that the first samples were
contaminated, and that CMV has no connection to alopecia areata (Tosti et.al. 1996). The results of a
study in year 2000 support the idea that CMV is neither a triggering factor for the immune response in
alopecia areata nor an activator of the autoimmunity (Offidani et.al. 2000). Perhaps the teenage girls and
other hair loss patients had another non-related disease whose side effects include hair loss.
The etiology of alopecia areata is complex and involves many factors. It appears to have both a
genetic and autoimmune basis. While scientists once believed that alopecia areata was itself, or was
associated with, an infectious disease, that belief is insignificant today. Evidence of strong family
history trends indicates that alopecia areata is, indeed, genetically based. Additionally, there are many
studies that support the hypothesis that alopecia areata is an autoimmune disease and lead to the
conclusion is that alopecia areata is mediated by autoimmune processes caused by chromosomal
mutations in the genome.
Current Treatment Methods
Available treatments for alopecia areata include: corticosteroids, topical anthralin, topical
minoxidil solution and contact sensitizers. Most of these therapies “bandage” the disease, stimulating
hair growth instead of solving the immune problem.
Corticosteroids
Corticosteroids have an anti-inflammatory and immunomodulatory effect. Immunomodulators
lessen the immune system’s ability to produce antibodies that recognize and react with the antigen that
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stimulated their production. Corticosteroids weaken the T-cell mediated immune attack on the hair
follicle (Kumaresan M. 2010). Based on the theory that alopecia areata is carried out through attack of
follicular autoantigens, treatment with corticosteroids should be successful at lessening the severity of
the disease.
Corticosteroids are heavily used in the treatment of alopecia areata. However, their efficacy
remains uncertain.
In one case study, eighteen patients with severe alopecia areata were given an oral dose of
prednisone daily. Terminal hair growth (satisfactory growth- over 50% of the scalp) occurred in seven
patients. Upon discontinuation of the drug, all the patients had a relapse. The researchers concluded
that although initial growth was observed, this therapy does not produce lasting effects. Moreover, it was
determined that the only way growth is retained after tapering the dosage or discontinuing the treatment
is if spontaneous remission occurs (Alabdulkareem et.al. 1998). Oral corticosteroid therapy is also not
recommended because of the adverse side effects (Nakajima et.al. 2007). Based on these results, one
can state that corticosteroid treatment mitigates disease symptoms while undergoing treatment but does
not cure the disease in one case.
The use of topical corticosteroid treatments yield slightly better results. In one study, five out
of twenty-eight patients (17.8%) had almost complete hair renewal after being treated with 0.05%
Clobetasol ointment. Eleven participants experienced painful folliculitis on the treated scalp (Tosti et.al.
2003). Although these results aren’t excellent, the researchers noted that all participants had already
undergone and failed to respond to topical immunotherapy. Therefore, they conclude that clobetasol
propionate under occlusion should be listed as an effective treatment (Tosti et.al. 2003). Patients apply
the ointment and then cover the area with plastic wrap, securing it to the skin with tape. Occlusion holds
perspiration close to the skin, hydrating the top layer of the epidermis. Topical medications are absorbed
into moist skin much more efficiently than with dry skin (Brannon, 2010).
Intralesional corticosteroids have an advantage over the oral and topical treatment options; this
treatment maximizes the effect of the corticosteroids by penetrating the skin and injecting its contents
straight into the affected tissue (Gregoriou et.al. 2011).
Doctors prescribe steroids with low solubility, this allows maximum action at the injection site
for they absorb very slowly (Kumaresan, M. 2010). The most common drugs used are triamcinolone
acetonide and betamethasone (Gregoriou et.al. 2011).
This method of treatment works best in groups of patients who have experienced less than 75%
scalp hair loss, who have had a shorter duration of hair loss, and in children (Kumaresan M. 2010).
However, a study using ten participants with over 50% loss showed that the treatment does work well
for patients with extensive loss. Six of the ten participants responded to treatment of intralesional
triamcinolone acetonide. The researchers concluded that the reason intralesional corticosteroids are not
generally used on patients with extensive loss is because it is painful and time consuming for the patient
This study also mentions that the average length of the episode of alopecia areata was the same in
responders and non-responders (Chang et.al. 2009). From this it can be determined that the treatment is
not curative, but can interfere with the pathogenesis of the disease while in use.
Another faster, less painful option is now being used to treat extensive alopecia areata. Instead of
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using conventional needles to apply the steroids, doctors use a multi-injection plate. There are several
advantages to this method. Firstly, it allows for the simultaneous injection in five to seven different
points at a fixed distance. This leads to uniformity in application, which may prevent skin atrophy.
Treatments are followed by a gentle massage, also to help spread the steroids evenly. Another advantage
is that the needle is long and the tip can reach the desired depth of the hair bulb where the drug is
delivered. The disadvantage to this treatment is that the needles are large, and if not handled gently, can
cause pain (Ferrando, Moreno-Arias 2000).
Although the aforementioned studies indicate that the intralesional treatment of alopecia areata is
beneficial to those with excessive hair loss, this method is still considered the best option for patients
with less than 50% loss (Kumaresan, M. 2010).
Minoxidil
Minoxidil is an antihypertensive vasodilator known to slow the onslaught of alopecia areata and
promote hair regrowth. Minoxidil’s exact mechanism is not known. However, tissue studies showed that
treatment with minoxidil causes an increase of follicles in anagen and a reduction of follicles in telogen.
This is indicated by the fact that after treatment, increased hair length is found on the forehead and other
areas of the body that do not usually grow long hairs. The abnormal growth, referred to as
hypertrichosis, suggests that the anagen phase of these follicles is of a longer duration (Messenger,
Rundegren 2003).
Cellular uptake studies in murine follicles showed that minoxidil and minoxidil sulphate
converged in the melanocytes and pigmented epithelial cells of the hair follicle. This is interesting
because previously mentioned studies implicate melanocytes as a possible source of autoantigens in
alopecia areata. If minoxidil binds to melanocytes, and then is observed to cause an increase in hair
growth, this observation can then serve as proof as to the role of melanocytes in the pathogenesis of
alopecia areata.
However, in this case, the researchers believed the reaction of minoxidil and melanin had no
bearing on the growth that resulted, as there was no evidence of minoxidil binding to non-pigmented
follicles although there was noted growth in both pigmented and non-pigmented follicles (Messenger,
Rundegren 2003). This was a significant realization, as alopecia areata does not affect non-pigmented
hair follicles.
Perhaps the mechanism that minoxidil uses does not include or affect the melanocytes but causes
growth in a way that both interferes with the pathogenesis of the disease and enhances growth of healthy
follicles as well. Or, maybe the minoxidil and melanin connection does exist and does reverse the
pathogenesis of the disease, as well as it enhances healthy, non-pigmented follicular growth by other
mechanisms. This would explain why there was excessive growth noted in non-pigmented hair follicles
as well.
The concentration of the active ingredient in minoxidil treatment can be varied. However, study
results imply that the treatment is more effective when higher concentrations of minoxidil are used. In
one experiment, forty-seven patients were treated with topical 1% minoxidil and forty-six patients were
treated with topical 5% minoxidil. Patients with extensive hair loss showed a response rate of 38% with
1% minoxidil, while those who received 5% minoxidil showed an 81% response rate (Fiedler-Weiss,
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1987).
In one double blind, placebo controlled study, researchers divided patients into two groups; eleven
patients received 3% topical minoxidil while fourteen other patients received a placebo. Hair growth
was observed in seven of the eleven patients (63.6%) in the minoxidil group and in five of the placebo
group (35%). Furthermore, 27% of the minoxidil group showed cosmetically acceptable hair growth
compared with 7.1% in the placebo group (Price, 1987). This study showed that treatment with 3%
minoxidil results in hair growth, even though the dosage is not as strong as 5% minoxidil drugs.
Although the topical 5% minoxidil treatment plan yields better results than the versions with lower
concentrations, it is also known to cause hypertrichosis on the face and neck, especially in children
(Wang et.al. 2012). Several patients also reported contact dermatitis as another adverse side effect. This
may be the reason that most treatment plans for alopecia areata include a low concentration of topical
minoxidil along with other drugs such as corticosteroids.
Studies also suggest that patients with minimal hair loss have a better chance of hair renewal with this
treatment than those patients with more hair loss. An early double-blind study observed that patients
with severe hair loss responded more weakly to treatment of topical 1% minoxidil than those with
moderate hair loss. Those with localized alopecia areata gained cosmetically acceptable hair regrowth
(Gregoriou et.al. 2011).
Anthralin
Treatment with anthralin is another possible option for achieving hair regrowth. In one study,
patients with extensive alopecia areata were treated with 0.5%- 1.0% anthralin cream. As a result of the
treatment, 25% had cosmetically acceptable hair renewal. All patients suffered from the same side
effects: intense itchiness, scaling, and erythema on the treated area (Fiedler-Weiss, Buys 1987).
However, in another study, only five of fifty-one patients treated with a mixture of 5% minoxidil
and 0.5% anthralin had cosmetically acceptable hair growth (Alsantali, 2011). While it is possible that
the co-treatment of minoxidil and anthralin has undesirable effects, it is more likely that there are other
factors involved. More research must be done on treatment of alopecia areata with anthralin in order to
render this treatment worthy.
Topical Immunotherapy
Diphenylcyclopropenone (DPCP) is a topical sensitizer used in the treatment of alopecia areata.
DPCP is a novel therapy because of its high success rate. It has a response rate of 60% in severe
alopecia areata and about 88 to 100% in patients with patchy alopecia areata (Singh, Lavanya 2010).
Perhaps its success rate is due to the fact that contact sensitization agents may modify antigen
presenting cells. The antigen presenting cells then have trouble recognizing autoantigens. This stops the
alopecia areata cycle (Hordinsky, Ericson 2004).
Generally, treatment is performed on the scalp. A cotton-tipped applicator soaked with 2%
acetone solution of DPCP is applied to an area on the scalp. Two weeks later, a 0.001% solution of
DPCP is applied. The solution should be retained on the scalp for forty-eight hours. The application is
repeated weekly, increasing the concentration each time until a mild dermatitis is observed (Singh,
Lavanya 2010). If the patient does not respond after six months, the patient should terminate DPCP
treatment.
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Out of fifty-four Greek alopecia areata patients that underwent immunotherapy, 83% responded.
All research participants had extensive alopecia, or long lasting alopecia. Twenty patients experienced
re-growth of terminal hair on the whole scalp; fifteen achieved re-growth of most terminal hair with
some remaining patches of alopecia; nine had sparse regrowth of pigmented, terminal hair; and one
patient observed regrowth of vellus hair. Terminal hair is dark, thick and long, while vellus hair is
described as short, fine and barely noticeable hair. Overall, the treatment was very successful.
Thirty-one patients had a relapse after conclusion of the treatment and underwent immunotherapy again
(Avgerinou et.al. 2007). The relapse rate is high, but according to the researchers, this may be due to the
failure of patients to undergo maintenance therapy once they experience cosmetically adequate regrowth
(Gregoriou et.al. 2011).
Topical immunotherapy can cause side effects such as persistent dermatitis, swollen lymph
nodes and contact leukoderma (Singh, Lavanya 2010).
Conclusions
Although some patients with alopecia areata have positive hair growth as a result of treatment,
most are disappointed. Many patients who respond to treatment initially experience a relapse as soon as
they taper the dosage or stop treatment. This is because most of the treatments that are currently
available to patients do not rectify the problems that cause alopecia areata. Rather, they are general hair
growth treatments that are nonspecific to alopecia areata. The best treatment option on the market today
is immunotherapy with DPCP. This is because the mechanism that DPCP uses actually alters the cells
that promote pathogenesis of alopecia areata. If more research is done into the etiology of alopecia
areata, newer treatments can be developed that target the disease’s pathogenic development.
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